Loading
MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.
MEN1703 (SEL24) is a small molecule (kinase inhibitor) developed by Ryvu Therapeutics. Its target is FLT3 (the sponsor names PIM/FLT3 kinase). ClinicalTrials.gov describes the intervention as: MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukaemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT06534437, plans to enrol 178 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small molecule (kinase inhibitor) directed at FLT3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to FLT3.
1.MEN1703 slips into a pocket on FLT3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MEN1703" OR ABSTRACT:"MEN1703" OR TITLE:"SEL24" OR ABSTRACT:"SEL24" OR TITLE:"Dapolsertib hydrochloride" OR ABSTRACT:"Dapolsertib hydrochloride") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MEN1703, not a curated reading list.
Shares Ryvu Therapeutics and the tag pipeline.
Shares Ryvu Therapeutics and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.
Shares Hodgkin lymphoma and the tag pipeline.